Practical AI for Drug Discovery and Preclinical Development Summit on January 30-February 01, 2024 in San Diego, United States

Although no drug on the market has yet been discovered using AI, we're due to witness an instantaneous transformation soon as AI approaches an inflection point in drug discovery thanks to the increase in collaboration between AI tech development and big pharma. This is evidenced by third-party investment in AI-enabled drug discovery more than doubling annually for the last five years.

With ongoing headlines spotlighting GSK, AZ, Novartis, Roche, Bayer, and Sanofi's positive results from their AI-powered drug discovery efforts, industry is teetering on the precipice of a breakthrough and the time to get involved is now!

Uniting computational and analytics experts to successfully capitalize on the transformative power of AI, the Practical AI for Drug Discovery and Preclinical Development Summit is your exclusive industry meeting to:

- Practically implement generative AI/ML tools that merge multiple data sources to better understand and drug new disease targets

- Develop tactics to overcome the data generation bottleneck and strategize on ways to make data universally accessible

- Improve vendor selection and qualification by better identifying new AI-native partners and manage existing partnerships to further integrate AI processes across functions

URLs:

Tickets: https://go.evvnt.com/1983317-2?pid=10008

Brochure: https://go.evvnt.com/1983317-3?pid=10008

Time: 9:00 AM - 4:30 PM

Prices:

Drug Developer Pricing - Conference + Pre-Conference Workshop Day: USD 4297.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Academic Pricing - Conference + Pre-Conference Workshop Day: USD 3697.00,

Academic Pricing - Conference Only: USD 2599.00,

Vendor Pricing - Conference + Pre-Conference Workshop Day: USD 5297.00,

Vendor Pricing - Conference Only: USD 3799.00

Speakers: Ajit Mohapatra, Director, Digital and AI Architecture and Engineering, GSK, Arvind Rao, Associate Professor, Computational Medicine and Bioinformatics, Radiation Oncology, University of Michigan, Christine Bakan, Global Head, Group Vice President, Computational Science and Informatics R AND D, Roche, Jadwiga Bienkowska, Senior Director and Head of Computational Biology and Oncology Research, Pfizer, Jens Kringelum, Vice President, Artificial Intelligence and Innovation, Evaxion Biotech, Martin Akerman, Co-Founder and Chief Technology Officer, Envisagenics, Matt Onsum, Head of Computing, Calico Life Sciences, Monica Wang, Head of Biologics and Novel Modalities Discovery and Capabilities, Products, Scientific Informatics, Takeda, Mridul Mehta, Chief AI Architect, GEn1E Lifesciences, Natnael Hamda, AI AND ML Research Scientist, Astellas Pharma, Nick Nystrom, Chief Technology Officer, Peptilogics, Peter Skewes-Cox, Director, Data Science, Novartis Biomedical Research, Petrina Kamya, Vice President, AI Platforms and President Insilco Medicine Canada, Insilico Medicine , Ruben Abagyan, Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences University of California , Sandor Szalma, Global Head, Genetics and Systems Biology, Takeda Development Center Americas, Inc., Uli Schmitz, Senior Director, Structural Chemistry, Gilead Sciences